Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MECAMYLAMINE HYDROCHLORIDE vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mecamylamine is a noncompetitive antagonist of nicotinic acetylcholine receptors (n ACh Rs) with highest affinity for α3β4 and α4β2 subtypes. It blocks ganglionic transmission in both sympathetic and parasympathetic ganglia, leading to decreased catecholamine release and antihypertensive effects.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
FDA: Management of moderately severe to severe essential hypertension and uncomplicated malignant hypertension.,Off-label: Treatment of Tourette syndrome, tics, and as an adjunct in smoking cessation.
Hypertension
Initially 2.5 mg orally twice daily, gradually increased by 2.5 mg increments at intervals of 2 or more days; usual maintenance dose 25 mg/day in divided doses.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal elimination half-life is approximately 12-24 hours; clinically, this allows once or twice daily dosing but requires dose adjustment in renal impairment.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Primarily hepatic with some renal excretion. Metabolized by cytochrome P450 enzymes, likely multiple isoforms, though specific enzymes not fully characterized.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Renal: 50-70% unchanged; biliary/fecal: minimal (less than 5%)
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Approximately 0-20% bound, primarily to albumin and alpha-1 acid glycoprotein; low binding is clinically insignificant.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Vd approximately 1-2 L/kg; extensive tissue distribution indicates high penetration into tissues.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: approximately 20-50% due to incomplete absorption and first-pass metabolism.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
Contraindicated in patients with renal insufficiency (e GFR <30 m L/min). For mild to moderate impairment, reduce dose by 50% and monitor closely.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), reduce dose by 50% and titrate slowly.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not recommended for use in children due to lack of safety and efficacy data.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Initiate at 2.5 mg once daily; increase slowly with careful monitoring due to increased sensitivity to hypotensive effects and higher risk of adverse effects.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None.
None
May cause orthostatic hypotension, syncope, and impaired mental alertness.,Caution in patients with poor renal function, prostatic hypertrophy, or pyloric stenosis.,Risk of rebound hypertension upon abrupt discontinuation.,Mecamylamine may precipitate urinary retention in patients with bladder dysfunction.
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Hypersensitivity to mecamylamine or any component.,Coronary artery disease (risk of precipitation of angina).,Recent myocardial infarction.,Glaucoma (may increase intraocular pressure).,Uremia.,Concurrent use with ganglionic blocking agents.
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid excessive alcohol intake as it may potentiate hypotensive effects. No specific food restrictions beyond maintaining a balanced diet.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
FDA Pregnancy Category C. Animal reproduction studies have not been conducted; potential fetal harm unknown. Mecamylamine crosses placenta. First trimester: theoretical risk of teratogenicity due to ganglionic blockade; avoid unless essential. Second/third trimester: may cause fetal hypotension, hypoxia, meconium aspiration, and neonatal respiratory depression due to maternal hypotension and reduced uterine blood flow. Neonatal withdrawal syndrome reported with chronic use.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Excreted in breast milk; M/P ratio not established. Risk of infant ganglionic blockade (hypotension, constipation, urinary retention). Contraindicated in breastfeeding due to potential for serious adverse effects.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
No established pregnancy-specific dose adjustments. Use lowest effective dose due to volume of distribution and clearance changes (increased plasma volume, renal clearance). Monitor closely for hypotension; consider dose reduction if significant maternal hypotension occurs.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Mecamylamine is a non-competitive antagonist of nicotinic acetylcholine receptors, used primarily for hypertension. It does not affect parasympathetic ganglia at therapeutic doses. Caution in patients with renal impairment as drug accumulation occurs. Avoid use in patients with glaucoma or pyloric stenosis due to anticholinergic effects.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take exactly as prescribed; do not skip doses or double up on missed doses.,Avoid driving or operating heavy machinery until you know how this medication affects you, as it can cause dizziness or blurred vision.,Report any signs of slow heart rate, fainting, difficulty urinating, or blurred vision to your healthcare provider immediately.,Do not stop taking this medication abruptly; your blood pressure may rise rapidly.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
"Mecamylamine, a noncompetitive nicotinic acetylcholine receptor antagonist used for hypertension, potentiates the vasodilatory effects of Manidipine, a dihydropyridine calcium channel blocker, by reducing sympathetic reflex responses that normally counteract calcium channel blocker-induced hypotension. This additive hypotensive effect can lead to severe hypotension, dizziness, syncope, and increased risk of falls or cardiovascular events, particularly in elderly patients or those with volume depletion."
"Mecamylamine, a noncompetitive antagonist of nicotinic acetylcholine receptors, blocks sympathetic ganglionic transmission, leading to reduced catecholamine release and hypotension. Phentolamine, a nonselective alpha-adrenergic antagonist, further inhibits vasoconstriction mediated by norepinephrine. Concurrent use results in additive hypotensive effects, increasing the risk of severe hypotension, orthostatic dizziness, and syncope, particularly during initial dosing or dose escalation."
"Mecamylamine, a ganglionic blocker, antagonizes nicotinic acetylcholine receptors, leading to sympatholytic effects. Nabilone, a synthetic cannabinoid, can increase heart rate via central sympathetic activation. The interaction results in Mecamylamine augmenting the tachycardic effects of Nabilone, potentially causing excessive heart rate elevation and risk of cardiac stress."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MECAMYLAMINE HYDROCHLORIDE vs ALDORIL D30, answered by our medical review team.
MECAMYLAMINE HYDROCHLORIDE is a Antihypertensive that works by Mecamylamine is a noncompetitive antagonist of nicotinic acetylcholine receptors (n ACh Rs) with highest affinity for α3β4 and α4β2 subtypes. It blocks ganglionic transmission in both sympathetic and parasympathetic ganglia, leading to decreased catecholamine release and antihypertensive effects.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MECAMYLAMINE HYDROCHLORIDE and ALDORIL D30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MECAMYLAMINE HYDROCHLORIDE is: Initially 2.5 mg orally twice daily, gradually increased by 2.5 mg increments at intervals of 2 or more days; usual maintenance dose 25 mg/day in divided doses.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MECAMYLAMINE HYDROCHLORIDE and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MECAMYLAMINE HYDROCHLORIDE is classified as Category C. FDA Pregnancy Category C. Animal reproduction studies have not been conducted; potential fetal harm unknown. Mecamylamine crosses placenta. First trimester: theoretical risk of ter. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.